Phase II Study of 90Y-Ibritumomab Tiuxetan for Elderly Patients with MCL


Phase II Study of 90Y-Ibritumomab Tiuxetan for Elderly Patients with MCL
Slides from a presentation at ICML 2013 and transcribed comments from a recent interview with Andrew M Evens, DO, MSc (10/26/13)
Jurczak W et al. Radioimmunotherapy as consolidation in MCL (mantle cell lymphoma) — 8 years follow-up of a prospective Phase 2 Polish Lymphoma Research Group study. Proc ICML 2013;Abstract 111.

Dr Evens is Professor of Medicine and Chief of the Division of Hematology/Oncology at Tufts University School of Medicine and Director of the Lymphoma Program and Leader of the Clinical Sciences Program at Tufts Cancer Center in Boston, Massachusetts.